[HTML][HTML] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL …
J Rausch, MM Dzama, N Dolgikh, HL Stiller… - …, 2023 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) represents a genetically heterogeneous group of myeloid
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …
[引用][C] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL …
J Rausch, MM Dzama, N Dolgikh, HL Stiller, SR Bohl… - 2023 - oparu.uni-ulm.de
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement …
J Rausch, MM Dzama, N Dolgikh, HL Stiller… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or
apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to …
apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to …
[引用][C] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or …
J Rausch, MM Dzama, N Dolgikh, HL Stiller… - …, 2023 - europepmc.org
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or
apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation …
apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation …
[HTML][HTML] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement …
J Rausch, MM Dzama, N Dolgikh, HL Stiller… - …, 2023 - haematologica.org
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or
apoptosis and sensitizes acute myeloid leukemia with <i>MLL</i> rearrangement or <i>NPM1</i> …
apoptosis and sensitizes acute myeloid leukemia with <i>MLL</i> rearrangement or <i>NPM1</i> …
[引用][C] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL …
J Rausch, MM Dzama, N Dolgikh, HL Stiller… - …, 2023 - oparu.uni-ulm.de
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or
apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 …
apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 …
[HTML][HTML] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement …
J Rausch, MM Dzama, N Dolgikh, HL Stiller… - …, 2023 - haematologica.org
Acute myeloid leukemia (AML) represents a genetically heterogeneous group of myeloid
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …
[引用][C] Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL …
NCT NCT04067336, NCT NCT05153330 - Haematologica, 2023 - europepmc.org
Acute myeloid leukemia (AML) represents a genetically heterogeneous group of myeloid
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …
neoplasms derived from early hematopoietic progenitors. Mutations in the NPM1 gene and …